Literature DB >> 34141033

Analysis of risk factors for early stent thrombosis in the Chinese population: A multicenter restrospective study.

Yu-Peng Wang1, Lei Ding1, Rui-Tao Zhang1, Xiao-Zeng Wang2, Dan-Qing Yu3, Shou-Yan Hao4, Jin-Wei Tian5, Zhen-Yu Liu6, Xiang-Qian Qi7, Hu Tan8, Hong-Yi Wu9, Feng-Hua Ding10, Li-Jun Guo1, Ya-Ling Han2.   

Abstract

BACKGROUND: The predictive scoring systems for early stent thrombosis (EST) remains blank in China. The study aims to evaluate the risk factors and conduct a prediction model of EST in the Chinese population.
METHODS: EST was defined as thrombosis that occurs within the first 30 days after primary percutaneous coronary intervention (PCI). Patients from ten Chinese hospitals diagnosed as stent thrombosis (ST) from January 2010 to December 2016 were retrospectively included as the study group. A control group (1 case:2 controls) was created by including patients without ST, major adverse cardiovascular events, or cerebrovascular events during follow-up. The present study evaluated 426 patients with single-vessel lesions and ultimately included 40 patients with EST and 80 control patients, who were included to identify factors that predicted EST and to develop a prediction scoring system. The other 171 patients without integrated 1:2 pair were used for external validation.
RESULTS: EST was independently associated with a low hemoglobin concentration (adjusted odds ratio [OR] 0.946, 95% confidence interval [95% CI] 0.901-0.993, P=0.026), a high pre-PCI Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score (OR 1.166, 95% CI 1.049-1.297, P=0.004), and a DAPT (DAPT) duration of <30 days (OR 28.033, 95% CI 5.302-272.834, P<0.001). The simple EST prediction score provided an area under the curve (AUC) of 0.854 (95% CI 0.777-0.932, P<0.001) with 70.0% sensitivity and 90.0% specificity, and 0.742 (95% CI 0.649-0.835, P<0.001) with 54.5% sensitivity and 81.0% specificity for external validation dataset.
CONCLUSIONS: EST may be independently associated with DAPT discontinuation within 30 days, a low hemoglobin concentration, and a high SYNTAX score. The scoring system also has a good ability to predict the risk of EST and may be useful in the clinical setting. Copyright: © World Journal of Emergency Medicine.

Entities:  

Keywords:  Coronary heart disease; Predictive scoring system; Risk stratification; Stent thrombosis

Year:  2021        PMID: 34141033      PMCID: PMC8188284          DOI: 10.5847/wjem.j.1920-8642.2021.03.005

Source DB:  PubMed          Journal:  World J Emerg Med        ISSN: 1920-8642


  14 in total

1.  Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis.

Authors:  Ehrin J Armstrong; Dmitriy N Feldman; Tracy Y Wang; Lisa A Kaltenbach; Khung-Keong Yeo; S Chiu Wong; John Spertus; Richard E Shaw; Robert M Minutello; Issam Moussa; Kalon K L Ho; Jason H Rogers; Kendrick A Shunk
Journal:  JACC Cardiovasc Interv       Date:  2012-02       Impact factor: 11.195

2.  Clinical end points in coronary stent trials: a case for standardized definitions.

Authors:  Donald E Cutlip; Stephan Windecker; Roxana Mehran; Ashley Boam; David J Cohen; Gerrit-Anne van Es; P Gabriel Steg; Marie-angèle Morel; Laura Mauri; Pascal Vranckx; Eugene McFadden; Alexandra Lansky; Martial Hamon; Mitchell W Krucoff; Patrick W Serruys
Journal:  Circulation       Date:  2007-05-01       Impact factor: 29.690

Review 3.  Predictors of stent thrombosis and their implications for clinical practice.

Authors:  Tommaso Gori; Alberto Polimeni; Ciro Indolfi; Lorenz Räber; Tom Adriaenssens; Thomas Münzel
Journal:  Nat Rev Cardiol       Date:  2019-04       Impact factor: 32.419

4.  Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial.

Authors:  Tullio Palmerini; Adriano Caixeta; Philippe Genereux; Ecaterina Cristea; Alexandra Lansky; Roxana Mehran; George Dangas; Dana Lazar; Rachel Sanchez; Martin Fahy; Ke Xu; Gregg W Stone
Journal:  Am Heart J       Date:  2012-03       Impact factor: 4.749

5.  A patient-level pooled analysis assessing the impact of the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials.

Authors:  Scot Garg; Giovanna Sarno; Chrysafios Girasis; Pascal Vranckx; Ton de Vries; Michael Swart; Marco Bressers; Hector M Garcia-Garcia; Gerrit-Anne van Es; Lorenz Räber; Gianluca Campo; Marco Valgimigli; Keith D Dawkins; Stephan Windecker; Patrick W Serruys
Journal:  JACC Cardiovasc Interv       Date:  2011-06       Impact factor: 11.195

6.  Long-term outcome after angiographically proven coronary stent thrombosis.

Authors:  Mohammad Almalla; Jörg Schröder; Vera Hennings; Nikolaus Marx; Rainer Hoffmann
Journal:  Am J Cardiol       Date:  2013-02-12       Impact factor: 2.778

7.  Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART).

Authors:  Takeshi Kimura; Takeshi Morimoto; Ken Kozuma; Yasuhiro Honda; Teruyoshi Kume; Tadanori Aizawa; Kazuaki Mitsudo; Shunichi Miyazaki; Tetsu Yamaguchi; Emi Hiyoshi; Eizo Nishimura; Takaaki Isshiki
Journal:  Circulation       Date:  2010-06-21       Impact factor: 29.690

8.  Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.

Authors:  Scot Garg; Giovanna Sarno; Patrick W Serruys; Alfredo E Rodriguez; Leonardo Bolognese; Maurizio Anselmi; Nicoletta De Cesare; Salvatore Colangelo; Raul Moreno; Stefania Gambetti; Monia Monti; Laura Bristot; Marco Bressers; Hector M Garcia-Garcia; Giovanni Parrinello; Gianluca Campo; Marco Valgimigli
Journal:  JACC Cardiovasc Interv       Date:  2011-01       Impact factor: 11.195

9.  Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry).

Authors:  Sabato Sorrentino; Gennaro Giustino; Usman Baber; Samantha Sartori; David J Cohen; Timothy D Henry; Serdar Farhan; Madhav Sharma; Cono Ariti; George Dangas; Michael Gibson; Michela Faggioni; Mitchell W Krucoff; Melissa Aquino; Jaya Chandrasekhar; David J Moliterno; Antonio Colombo; Birgit Vogel; Alaide Chieffo; Annapoorna S Kini; Bernhard Witzenbichler; Giora Weisz; Philippe Gabriel Steg; Stuart Pocock; Roxana Mehran
Journal:  Am J Cardiol       Date:  2018-08-20       Impact factor: 2.778

10.  Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).

Authors:  Philippe Généreux; Gregg W Stone; Robert A Harrington; C Michael Gibson; Ph Gabriel Steg; Sorin J Brener; Dominick J Angiolillo; Matthew J Price; Jayne Prats; Laura LaSalle; Tiepu Liu; Meredith Todd; Simona Skerjanec; Christian W Hamm; Kenneth W Mahaffey; Harvey D White; Deepak L Bhatt
Journal:  J Am Coll Cardiol       Date:  2013-10-30       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.